Clinical Trials Directory

Trials / Completed

CompletedNCT00878995

Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma

Nutrition and Anabolic Interventions in Squamous Cell Carcinoma

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
28 (actual)
Sponsor
The University of Texas Medical Branch, Galveston · Academic / Other
Sex
Female
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Testosterone may lessen weight loss and improve muscle size and strength in patients with cachexia caused by cancer. PURPOSE: This randomized phase I trial is studying whether testosterone administered during standard of care chemotherapy and/or radiation works by helping patients with squamous cell carcinoma to maintain their body weight and muscle size and strength during treatment.

Detailed description

OBJECTIVES: * To determine the effect of testosterone therapy on lean body mass and muscle strength in patients with advanced or recurrent squamous cell carcinoma. * To determine the testosterone therapy on inflammatory biomarkers in patients with advanced or recurrent squamous cell carcinoma. OUTLINE: Patients are stratified according to age and disease stage. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive standard of care chemotherapy and/or radiation and placebo testosterone intramuscularly (IM) weekly for 7 weeks. * Arm II: Patients receive standard of care chemotherapy and/or radiation and testosterone IM weekly for 7 weeks. Patients undergo dual energy x-ray absorptiometry, muscle strength tests, stable isotope metabolic studies, indirect calorimetry studies, and assessment of their physical activity level, and nutritional counseling. Patients also complete mood, fatigue, and quality-of-life questionnaires. Blood, muscle tissue, and urine samples are collected periodically for laboratory studies. Samples are analyzed for serum inflammatory biomarkers and inflammatory cytokines by immunoassay. After completion of study treatment, patients are followed periodically for 1 year.

Conditions

Interventions

TypeNameDescription
DRUGPlacebo TestosteronePlacebo (Saline) Testosterone given IM once per week.
DRUGTestosterone Enanthate 100 MG/MLTestosterone Enanthate 100mg/ml given once per week IM.

Timeline

Start date
2009-06-03
Primary completion
2014-06-01
Completion
2015-06-01
First posted
2009-04-09
Last updated
2018-03-12
Results posted
2018-03-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00878995. Inclusion in this directory is not an endorsement.